Company: ACBM
Filing Date: 2025-07-22
Form Type: 10-Q
Source: 0001640334-25-001257
Chunk: 15

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-07-22
Form: 10-Q
Item: Item 1
Chunk 15
---
31, 2023

              Additional  Deferred     Total   Preferred Stock  Common Stock  Paid in  Stock  Accumulated  Stockholders'   Shares  Amount  Shares  Amount  Capital  Compensation  Deficit  Equity                          Balance, December 31, 2022  -  $-   60,042,000  $60,042  $32,295,236  $(8,060,983 ) $(23,807,925 ) $486,370                                  Amortization of deferred stock compensation  -   -   -   -   -   3,928,100   -   3,928,100 Imputed interest on related party loans  -   -   -   -   788   -   -   788 Net loss  -   -   -   -   -   -   (4,004,354 )  (4,004,354 )                                 Balance, March 31, 2023  -  $-   60,042,000  $60,042  $32,296,024  $(4,132,883 ) $(27,812,279 ) $410,904 

The accompanying notes are an integral part of these unaudited financial statements.

 6Table of Contents

ACRO BIOMEDICAL CO., LTD.

Statements of Cash Flows

(Unaudited) 

   Three months ended     March 31,    2024  2023        CASH FLOWS FROM OPERATING ACTIVITIES      Net loss $(11,252) $(4,004,354)Adjustments to reconcile net loss to net cash used in operating activities:        Imputed interest - related parties  954   788 Amortization of deferred stock compensation   -   3,928,100 Changes in operating assets and liabilities:        Accounts receivable  -   30,000 Prepaid expenses  1,250   (11,315)Change in operating lease liability  (2,315)  - Accounts payable